1. Are PAR exploring any non-dilutive forms of funding?
2. Assuming a shortfall in funding for the OA program, will PAR look to dial back on some of the other programs they do not expect will generate revenue/partnership deals in the near future?
3. Why did PAR not disclose to the market at an earlier time about the adverse tissue finding found in PPS-treated rats?
4. An update on the three other treatments PAR were looking to repurpose?
PAR Investor Meeting - Questions from HC, page-5
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.005(2.56%) |
Mkt cap ! $70.04M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 21.0¢ | 19.5¢ | $80.51K | 398.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 112938 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 4396 | 1 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |